Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Psyence Biomedical ( (PBM) ) just unveiled an announcement.
On August 15, 2025, Psyence Biomedical Ltd. entered into a subscription agreement with Psyence Labs Ltd., acquiring 1,750 shares at $2,000 each, totaling $3,500,000. The transaction, which closed on September 1, 2025, strengthens Psyence Biomedical’s investment in Psyence Labs, a company specializing in psychedelic pharmaceutical ingredients. This move may enhance Psyence Biomedical’s market position in the psychedelic pharmaceutical industry, potentially benefiting stakeholders through expanded research and development capabilities.
More about Psyence Biomedical
Psyence Biomedical Ltd. operates in the pharmaceutical industry, focusing on the development and production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development. The company is involved in psychedelic cultivation and extraction, exporting raw materials and extracts to research partners, and developing proprietary extraction methodologies.
Average Trading Volume: 1,662,230
Technical Sentiment Signal: Sell
Current Market Cap: $1.84M
Find detailed analytics on PBM stock on TipRanks’ Stock Analysis page.